阿托伐他汀强化降脂对择期冠脉介入治疗术后C反应蛋白的影响

The Effect of Intensive Lipid Lowering Therapy By Atorvastatin on C-Reactive Protein in Patients after Selective Percutaneous Coronary Intervention

目的:本研究旨在观察阿托伐他汀强化降脂对择期经皮冠脉介入治疗(PCI)术后血清C反应蛋白(CRP)的影响。方法:选择行冠脉择期pCI的冠心病患者40例,随机分成治疗组和对照组,对照组给予常规抗缺血治疗,同时给予阿托伐他汀10mg,每日1次口服,治疗组在上述常规药物治疗的基础上,于PCI术前72h将阿托伐他汀加量至40mg,每日1次口服,所有病人均在入院时、冠脉介入治疗术后24h检测CRP。结果:冠脉介入治疗(PCI)术后,治疗组CRP明显低于同期对照组。结论:阿托伐他汀强化降脂能明显降低冠脉PCI术后CRP水平。

Objective：The study aimed to evaluate the effect of intensive lipid lowering therapy by amrvastatin on C-reactive protcin（CRP） in patients attcr selective percutaneous coronary intervention（PCI）.Methods：40 patients with coronary heart disease undcrgoing selective PCI was random!y divided into two groups.The control group was commonly administrated anti-ischemic therapy, simultaneously with atrvastatin（10mg one rime per day oratly）.In the treamaent group atorvastatin was added to 40mg one time pcr day orally at preoperative 72 hours.on the basis of above common /herapy.All the patients were admitted to hospital, the detection of CRP at 24 hours after coronary interveution.Results：The CRP of treatment group was obviously lower than that of control group after PCI. Conclusion：lntcnsive lipid lowering therapy by atorvastatin can significantly cut down the level of CRP after PCI.